|Application ||WB, IHC|
|Calculated MW||16693 Da|
|Other Names||Protein phosphatase 1 regulatory subunit 14A, 17 kDa PKC-potentiated inhibitory protein of PP1, Protein kinase C-potentiated inhibitor protein of 17 kDa, CPI-17, PPP1R14A, CPI17, PPP1INL|
|Target/Specificity||A synthetic peptide corresponding to residues in the N-term of human CPI-17 aplha was used as immunogen. This antibody may also detect isoform CPI-17 beta.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CPI-17 alpha Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Inhibitor of PPP1CA. Has over 1000-fold higher inhibitory activity when phosphorylated, creating a molecular switch for regulating the phosphorylation status of PPP1CA substrates and smooth muscle contraction.|
|Tissue Location||Isoform 1 is detected in aorta and testis. Isoform 2 is detected in aorta.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PKC Potentiated Inhibitor Protein-17 (CPI-17) is a 17 kDa protein (1). Expressed in smooth muscles and neuronal cells, CPI-17 is a myosin phosphatase inhibitor protein. Phosphorylation of CPI-17 at Thr38 enhances its inhibitory effect by 100 fold (2). Once phosphorylated, CPI-17 inhibits PP1c and MLCP holoenzyme activity (3).
1. Eto M, Ohmori T, Suzuki M, Furuya K & Morita F (1995). J Biochem 118, 1104-1107
2. Eto M, Senba S, Morita F & Yazawa M (1997). FEBS Lett 410, 356-360
3. Senba S, Eto M & Yazawa M (1999). J Biochem 125, 354-362
If you have any additional inquiries please email technical services at email@example.com.